

1 **Title**

2 Year-round RSV Transmission in the Netherlands Following the COVID-19 Pandemic - A  
3 Prospective Nationwide Observational and Modeling Study

4 **Authors**

5 Yvette N. Löwensteyn (1)\*, Zhe Zheng (2)\*, Neele Rave (1), Michiel A.G.E. Bannier (3),  
6 Marie-Noëlle Billard (1), Jean-Sebastien Casalegno (4), Virginia E. Pitzer (2), Joanne G.  
7 Wildenbeest (1), Daniel M. Weinberger (2), Louis Bont (1), on behalf of the SPREAD study  
8 group♦

9

10 **Affiliations**

11 (1) Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's  
12 Hospital, P.O. Box 85090, 3508 AB Utrecht, the Netherlands

13 (2) Department of Epidemiology of Microbial Diseases and the Public Health Modeling Unit,  
14 Yale School of Public Health, New Haven, CT, USA

15 (3) Department of Pediatric Respiratory Medicine, Maastricht University Medical Center,  
16 Maastricht, the Netherlands

17 (4) Department of Microbiology, Hospices Civils de Lyon, Lyon University Medical Center,  
18 Lyon, France

19

20 **Correspondence**

21 Louis Bont, Department of Pediatric Immunology and Infectious Diseases, Wilhelmina  
22 Children's Hospital, P.O. Box 85090, 3508 AB Utrecht, the Netherlands. E-mail:

23 [l.bont@umcutrecht.nl](mailto:l.bont@umcutrecht.nl)

24

25 \*Shared first authorship

26 ♦SPREAD study group collaborators:

27 Marlies Vermaas - van Putten (Admiraal de Ruyter Ziekenhuis), Elly Smit-Kleinlugtenbeld

28 (Albert Schweitzer Ziekenhuis), Marieke Peetsold (Alrijne Ziekenhuis), Martijn van der Kuip,

29 Hans van Goudoever, Britt van Keulen (Amsterdam Universitair Medisch Centrum), Anouk

30 Boot, Robin Kloos (St. Antonius Ziekenhuis), Sandy van Gool (Antonius Zorggroep Sneek),

31 Yvonne Snepvangers (Beatrix Ziekenhuis), Anke Kuijpers (Bernhoven Ziekenhuis), Negassi

32 Menelik (BovenIJ Ziekenhuis), Stephanie de Crom (Bravis Ziekenhuis), Carien Miedema

33 (Catharina Ziekenhuis), Gavin ten Tusscher, Jet van Giessen (Dijklander Ziekenhuis), Ronald

34 de Moor (Elizabeth-TweeSteden Ziekenhuis), Marianne Faber, Mijke Breukels (Elkerliek

35 Ziekenhuis), Vincent Jaddoe, Liesbeth Duijts (Erasmus Medisch Centrum), Claire Lutterman

36 (Flevoziekenhuis), Ilka Vink, Gerdien Tramper-Stranders (Franciscus Gasthuis & Vlietland),

37 Annemarie Oudshoorn, Astrid Ritman (Gelre Ziekenhuis), Gerdien Dubbink-Verheij (Groene

38 Hart Ziekenhuis), Jantien Bolt, Cagri Cakir (Haaglanden Medisch Centrum), Edwin Rietveld

39 (IJsselland Ziekenhuis), Jolita Bekhof (Isala), Edmond Rings, Jara de Swart (Leids

40 Universitair Medisch Centrum), Gertjan Driessen (Maastricht University Medical Center),

41 Rienus Doedens (Martini Ziekenhuis), Lieke Nijssen, Lonneke van Onzenoort - Bokken

42 (Maxima Medisch Centrum), Ruud Meijneke (Meander Medisch Centrum), Machteld van

43 Scherpenzeel, Tina Faber (Medisch Centrum Leeuwarden), Femke de Groof (Noordwest

44 Ziekenhuisgroep), Julia van de Zande, Monique op de Coul (Onze Lieve Vrouw Gasthuis),

45 Stefanie Henriët, Kim Stol (Radboud Universitair Medisch Centrum), Maaïke van Rossem

46 (Rijnstate Ziekenhuis), Monique Jacobs (Slingeland Ziekenhuis), Marlies van Houten

47 (Spaarne Gasthuis), Roy Zuurbier, Frans Plötz (Tergooi Medisch Centrum), Andra de Vries

48 (Treant Zorggroep), Rinske van der Heide (Universitair Medisch Centrum Groningen),

49 Anneke van Boekholt (VieCuri), Gienke Gonera - de Jong (Wilhelmina Ziekenhuis Assen),  
50 Amara Nassar - Sheikh Rashid, Manouck Roelofs (Zaans Medisch Centrum), Károly Illy  
51 (Ziekenhuis Rivierenland), Naomi Reijmerink (Ziekenhuis St Jansdal), Stefan van Dorth  
52 (Ziekenhuis Tjongerschans), Saskia Schipper (ZorgSaam), Philippe Rosias (Zuyderland  
53 Medisch Centrum), Anne Teirlinck (Rijksinstituut voor Volksgezondheid en Milieu)

54

55 **Word count**

56 Abstract: 50/50

57 Manuscript: 1499/1500

58 **ABSTRACT**

59 A nationwide prospective study showed year-round RSV transmission in the Netherlands after  
60 an initial 2021 summer outbreak. The pattern was unprecedented and distinct from  
61 neighboring countries. Our dynamic simulation model suggests that this transmission pattern  
62 could be associated with waning immunity because of low RSV circulation during the  
63 COVID-19 pandemic.

64

65 **Keywords.** Respiratory syncytial virus; transmission; epidemic timing; seasonality; COVID-  
66 19; waning immunity; immunity debt

67        **INTRODUCTION**

68            Before the COVID-19 pandemic, RSV epidemics occurred annually during winter in  
69    temperate climates (**Figure 1A**). During winter 2020/2021, RSV was virtually absent  
70    following the implementation of COVID-19-related non-pharmaceutical interventions (NPIs)  
71    [1, 2]. After NPIs relaxed, various patterns of re-emergent RSV epidemics were observed in  
72    different countries. Several studies suggested that school reopening is associated with  
73    increased RSV activity [1, 3]. However, little attention has been paid to the impact of  
74    increased RSV susceptibility in children and adults due to low RSV exposure during the  
75    pandemic (“immunity debt”) on the patterns of resurgence [4].

76            Using a combination of prospective surveillance data from the Netherlands and  
77    simulation models, this study aims to (1) describe the unusual endemic pattern of RSV  
78    between May 2021 and August 2022 and (2) illustrate the impact of waning population  
79    immunity on the timing, intensity, and persistence of the re-emergent RSV epidemic. This  
80    study provides an opportunity to advance our understanding of the drivers of re-emergent  
81    RSV epidemics.

## 82 **METHODS**

### 83 **Study Design**

84 We initiated a prospective nationwide surveillance study (SPREAD study: surveillance of  
85 pediatric respiratory admissions in Dutch hospitals) in which real-time data are collected on  
86 RSV-related pediatric hospitalizations in 46 hospitals throughout the Netherlands  
87 (**Supplementary Table 1**). In 10 hospitals with standard-of-care RSV testing, clinical patient  
88 data are collected (**Supplementary Figure 1**). For this paper, we collected data from May 3,  
89 2021 (week 18) until September 4, 2022 (week 35). Age-stratified data were collected from  
90 October 2018 until June 2022. The study population included all children between 0-2 years  
91 of age who were hospitalized with RSV-bronchiolitis in participating hospitals.

92 Collaborators of participating hospitals were requested to share data on a weekly basis.  
93 Follow-ups and data verification were performed by the study team to ensure data quality.  
94 Data were entered into the Castor Electronic Data Capture (EDC) system [5]. We analyzed  
95 potential differences in the age distribution of patients during the following periods: pre-  
96 COVID-19 (2018/2019 and 2019/2020 winter season (October-April)), post-COVID-19  
97 summer outbreak (May-August 2021) and post-COVID-19 endemic phase (September 2021-  
98 August 2022). Retrospective data were collected using diagnosis treatment combination (DBC)  
99 codes (3210 - RSV-bronchiolitis; 3208 - lower respiratory tract infection; 3104 - upper  
100 respiratory tract infection), and RSV-positive admissions were manually selected using  
101 patient files. We used the Mann-Whitney-U test to determine statistically significant  
102 differences (defined as  $p < 0.05$ ) between subgroups. Analyses were performed with SPSS  
103 version 26.0 (IBM Corp, Armonk, NY).

104

### 105 **Evaluating Different Hypotheses Using Simulation Models**

106 We modified our previously published age-stratified RSV transmission model that accounts  
107 for population dynamics, RSV seasonality, and virus importation from external sources to  
108 account for waning immunity (**Supplementary Modeling Methodology**) [6]. Our previous  
109 model assumed that individuals gain partial immunity following infection, which reduces  
110 their susceptibility to subsequent infections. By adding waning immunity, we assumed that  
111 individuals can become susceptible to infection after a long period of low virus exposure.

112 Several factors could explain differences in the timing and intensity of RSV epidemics  
113 before and after the COVID-19 pandemic, including length and strength of NPIs, RSV  
114 importation from external sources, increased birth rate in the Netherlands during COVID-19,  
115 and waning population immunity against RSV due to absent RSV circulation. We simulated  
116 RSV transmission from July 2018 to June 2025 to evaluate the various factors' impact on the  
117 projected trajectories of RSV hospitalizations and qualitatively compared these to the  
118 observed re-emergent RSV epidemic in the Netherlands. The four scenarios that we evaluated  
119 were (1) moderate level of NPIs and low level of virus importation, no waning immunity; (2)  
120 moderate level of NPIs and low level of virus importation, with waning immunity; (3)  
121 moderate level of NPIs and high level of virus importation, with waning immunity; (4) strict  
122 NPIs but high level of virus importation, with waning immunity (**Supplementary Table 5**).  
123 We developed a free-to-use web-based Shiny app to allow researchers to simulate re-  
124 emergent RSV under the impact of various factors. We provide an interactive example at  
125 <https://3wxpl3-zhe-zheng.shinyapps.io/shiny/>. Data and code to reproduce this study are  
126 available from GitHub (<https://github.com/weinbergerlab/SPREAD.git>).

127

## 128 **RESULTS**

### 129 **RSV-related Pediatric Hospitalizations**

130 Starting from May 24, 2021 (week 21), a summer outbreak of RSV was observed. During the  
131 peak week (July 19, week 29), 240 patients were admitted with RSV-bronchiolitis.  
132 Subsequently, continuous RSV transmission was observed, with RSV-related admissions  
133 stabilizing at approximately 50 patients weekly (**Figure 1B**).

134

### 135 **Older Patients During and After the 2021 Summer Outbreak**

136 We obtained age-stratified data for 988 patients admitted with RSV infection for 2018-2022  
137 in 10 hospitals (**Supplementary Table 2**). The proportion of patients <6 months was higher  
138 during pre-COVID-19 winter seasons. Median age during pre-COVID-19 winter seasons  
139 2018/2019 and 2019/2020 was 69 days (IQR 35-176). During the summer outbreak, median  
140 age increased to 161 days (IQR 56-383) ( $p<0.001$ ). During the endemic phase (September  
141 2021 - August 2022), median age decreased again to 137 days (IQR 54-281) but was still  
142 higher than during pre-COVID winter seasons ( $p<0.001$ ) (**Supplementary Figure 2**). As a  
143 sensitivity analysis, we excluded patients from the only academic hospital (UMCU), which  
144 contributed a large number of patients (21% pre-COVID-19 versus 11% during the summer  
145 outbreak and 14% during the endemic phase). Differences between groups remained  
146 unchanged (**Supplementary Table 3**).

147

### 148 **Association of Waning Population Immunity with RSV Epidemic Timing**

149 A model that assumed moderate NPIs, low virus importation, and waning population  
150 immunity against RSV due to low RSV circulation (Scenario 2) most closely resembled the  
151 Dutch situation: a large summer outbreak followed by continuous RSV transmission (**Figure**  
152 **2**). Under this scenario, the proportion of RSV hospitalizations in children >1 year was  
153 expected to be higher during the summer outbreak than during a typical winter season. This



154 proportion decreased over time during the following “endemic” phase. Alternative scenarios  
155 that assumed no waning RSV immunity failed to generate a summer outbreak in 2021 that  
156 was more intense than previous winter epidemics (**Supplementary Figure 4A**). A model that  
157 assumed strict NPIs, high level of virus importation, and waning immunity after a prolonged  
158 period of low viral exposure (Scenario 4) most closely resembled RSV activity in Germany  
159 and France: RSV activities returned to normal winter epidemics after a small outbreak in  
160 Spring 2021 (**Supplementary Figure 4C**).

161

## 162 **DISCUSSION**

163           The Netherlands exhibited a unique pattern of RSV re-emergence during the COVID-  
164 19 pandemic characterized by a high summer peak in 2021 followed by a prolonged period of  
165 continuous transmission at mid- to high-level RSV activity. Our model simulations confirm  
166 that population “immunity debt” can explain the large RSV summer outbreak and the  
167 following “endemic phase” (**Supplementary Figure 5**) [4, 7-9]. Additionally, NPIs were  
168 gradually re-implemented between mid-November 2021 and end-of-January 2022. This  
169 combined with school holidays in December and mid-February may also have contributed to a  
170 stagnation of RSV activity.

171           The year-round continuous RSV transmission pattern is distinctive not only from pre-  
172 pandemic winter epidemics in the Netherlands but also from neighboring countries such as  
173 Germany and France. These two countries returned to a winter epidemic in 2021 with low  
174 RSV activity during the summer of 2022. NPIs strictness and virus importation from external  
175 sources could explain these observed variations in RSV seasonality as these factors shape the  
176 level of population immunity debt [6, 9] (**Supplementary Figure 4C**). Furthermore,  
177 differences in surveillance and reporting strategies may explain the observed difference.

178           Our results suggest that although a shift in RSV seasonality may occur after  
179 implementation and subsequent relaxation of NPIs, RSV activity will most likely return to  
180 normal epidemic timing because herd immunity against RSV infection will return to pre-  
181 pandemic levels after two seasons of RSV exposure. To date, our model projection is aligned  
182 with the national RSV activity report from the National Institute for Public Health and the  
183 Environment (RIVM) [10].

184           Our study has several limitations. First, since not all participating hospitals used  
185 standard RSV testing, we may have underestimated RSV-related hospitalization rates. Some  
186 hospitals only used standard testing during the summer outbreak, which may have led to the

187 underestimation of hospitalizations after the outbreak. Second, data collection was not  
188 standardized for each hospital. Although most hospitals shared prospective data, some used  
189 DBC codes or virology results to collect retrospective data. Third, we received consistent data  
190 from 34/46 hospitals for the entire study period. This may have led to underestimation of  
191 hospitalization rates. Lastly, our model was not calibrated to the observed hospitalization data  
192 in the Netherlands due to the short observational period. Instead, we simulated RSV  
193 epidemics using parameters from previous RSV models in the United States based on Dutch  
194 demographics. Although our simulations may not perfectly resemble the re-emergent RSV  
195 epidemics in the Netherlands, the flexible parameter ranges in our web-based app provide an  
196 opportunity for researchers from other countries to simulate re-emergent epidemics based on  
197 their local demographic and epidemiological characteristics.

198         In summary, we describe a distinct pattern of ongoing RSV transmission following an  
199 out-of-season RSV outbreak in the Netherlands after relaxation of COVID-19-related NPIs.  
200 The pattern is different from neighboring countries and may be partly explained by “immunity  
201 debt”, i.e. waning population immunity after a long period of low RSV exposure. Continuous  
202 monitoring of RSV seasonality using hospital-based data is essential to anticipate future RSV  
203 epidemics.

204 **NOTES**

205 **Acknowledgments**

206 The authors thank the children and their families who participated in the study; Eline Bel,  
207 Katja Steenhuis, Marit de Bruijne, Kiora Russel, Nathalie Oldenburger, Kayleigh  
208 Vievermanns, Kim Bodaar, and Arda Yilmaz for their assistance in data collection; and all  
209 nurses, nurse practitioners, supporting staff, doctors and pediatricians for their substantial and  
210 ongoing effort for this study. Lastly, the authors thank the Dutch Working Group on Clinical  
211 Virology (NWKV) from the Dutch Society for Clinical Microbiology (NVMM) and all  
212 participating laboratories for providing the virological data from the weekly laboratory  
213 virological report.

214

215 **Disclaimer**

216 The funder has no role in the design and conduct of the study; collection, management,  
217 analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or  
218 decision to submit the manuscript for publication.

219

220 **Financial support**

221 This work was supported by ZonMw and the National Institute of Allergy and Infectious  
222 Diseases (MIDAS Program) of the U.S. National Institutes of Health under award number  
223 R01AI137093. The content is solely the responsibility of the authors and does not necessarily  
224 represent the official views of the National Institutes of Health.

225

226 **Potential conflicts of interest**

227 Louis Bont has regular interaction with pharmaceutical and other industrial partners. He has  
228 not received personal fees or other personal benefits. University Medical Centre Utrecht

229 (UMCU) has received major funding (>€100,000 per industrial partner) for investigator-  
230 initiated studies from AbbVie, MedImmune, Janssen, the Bill and Melinda Gates Foundation,  
231 Nutricia (Danone) and MeMed Diagnostics. UMCU has received major cash or in kind  
232 funding as part of the public private partnership IMI-funded RESCEU project from GSK,  
233 Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. University Medical Centre Utrecht has  
234 received major funding by Julius Clinical for participating in the INFORM study sponsored  
235 by MedImmune. UMCU has received minor funding for participation in trials by Regeneron  
236 and Janssen from 2015-2017 (total annual estimate less than €20,000). UMCU received minor  
237 funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria  
238 Nordic, MabXience, Novavax, Pfizer, Janssen (total annual estimate less than €20,000). Louis  
239 Bont is the founding chairman of the ReSViNET Foundation. Virginia Pitzer has received  
240 reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements on  
241 respiratory syncytial virus. Daniel Weinberger has received consulting fees from Pfizer,  
242 Merck, GSK, Affinivax, and Matrivax for work unrelated to this manuscript and is the  
243 principal investigator on research grants from Pfizer and Merck on work unrelated to this  
244 manuscript. Zhe Zheng is expected to receive consulting fees from Pfizer for work unrelated  
245 to this manuscript. No other conflicts of interest exist. All authors have submitted the ICMJE  
246 Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider  
247 relevant to the content of the manuscript have been disclosed.

248

## REFERENCES

- 249 1. Billard MN, van de Ven PM, Baraldi B, Kragten-Tabatabaie L, Bont LJ, Wildenbeest  
250 JG. International changes in respiratory syncytial virus (RSV) epidemiology during  
251 the COVID-19 pandemic: Association with school closures. *Influenza and other  
252 respiratory viruses* **2022**; 16(5): 926-36.
- 253 2. van Summeren J, Meijer A, Aspelund G, et al. Low levels of respiratory syncytial  
254 virus activity in Europe during the 2020/21 season: what can we expect in the coming  
255 summer and autumn/winter? *Eurosurveillance* **2021**; 26(29).
- 256 3. Li Y, Wang X, Cong B, Deng S, Feikin DR, Nair H. Understanding the Potential  
257 Drivers for Respiratory Syncytial Virus Rebound During the Coronavirus Disease  
258 2019 Pandemic. *The Journal of infectious diseases* **2022**; 225(6): 957-64.
- 259 4. Billard MN, Bont LJ. Quantifying the RSV immunity debt following COVID-19: a  
260 public health matter. *Lancet Infect Dis* **2022**.
- 261 5. Castor Electronic Data Capture system. 2021 Available at:  
262 <https://www.castoredc.com/electronic-data-capture-system/>. Accessed February 9.
- 263 6. Zheng Z, Pitzer VE, Shapiro ED, Bont LJ, Weinberger DM. Estimation of the Timing  
264 and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-  
265 19 Pandemic in the US. *JAMA Netw Open* **2021**; 4(12): e2141779.
- 266 7. Reicherz F, Xu RY, Abu-Raya B, et al. Waning immunity against respiratory syncytial  
267 virus during the COVID-19 pandemic. *The Journal of infectious diseases* **2022**.
- 268 8. Bardsley M, Morbey RA, Hughes HE, et al. Epidemiology of respiratory syncytial  
269 virus in children younger than 5 years in England during the COVID-19 pandemic,  
270 measured by laboratory, clinical, and syndromic surveillance: a retrospective  
271 observational study. *Lancet Infect Dis* **2022**.
- 272 9. Koltai M, Krauer F, Hodgson D, et al. Determinants of RSV epidemiology following  
273 suppression through pandemic contact restrictions. *Epidemics* **2022**; 40: 100614.
- 274 10. RIVM. State of affairs RS (respiratory syncytial) virus. RS virus no longer increased  
275 in the Netherlands. 2022 Available at: [https://www.rivm.nl/rs-virus/stand-van-zaken-  
276 rs-virus](https://www.rivm.nl/rs-virus/stand-van-zaken-rs-virus).
- 277 11. ECDC. Data on country response measures to COVID-19. 2022 Available at:  
278 [https://www.ecdc.europa.eu/en/publications-data/download-data-response-measures-  
279 covid-19](https://www.ecdc.europa.eu/en/publications-data/download-data-response-measures-covid-19).


280

281 **TABLES AND FIGURES**

282

283 **Figure 1.** Respiratory Syncytial Virus Activity in the Netherlands.

284 A. Respiratory Syncytial Virus Activity in the Netherlands Before the COVID-19 Pandemic.



285


286 Source: Weekly virological surveillance of Dutch Working Group for Clinical Virology of the  
287 Dutch Society for Medical Microbiology (NVMM) and RIVM.

288

289

290 B. Weekly Number of Children Younger Than 2 Years of Age Admitted with RSV Infection  
291 in The Netherlands Between May 2021 - August 2022.

292




293

294 Grey shaded areas = period of school closure.



295 **Figure 2.** Simulated number of monthly respiratory syncytial virus (RSV) hospitalizations in  
296 children <2 years of age in the Netherlands, 2018–2025, for the model including waning of  
297 immunity.

298



299

300 The year 2018-2019 corresponds to the RSV hospitalizations before the COVID-19 pandemic.

301 We assumed that COVID-19-related public health measures started in April 2020 and

302 gradually relaxed since March 2021 over a 3-month period [11]. The projected RSV

303 hospitalizations after the interruption of COVID-19-related measures over time are plotted for

304 2021 to 2025. The green line corresponds to the total RSV hospitalizations in children under 2

305 years of age. The orange line corresponds to the RSV hospitalizations in infants under 6

306 months of age. The purple line corresponds to the RSV hospitalizations in children 1 year of

307 age. The shaded area corresponds to the period of the SPREAD study, May 2021 - August

308 2022.